Scientific Sessions 2025  /  Inflammation in Preclinical vs. Clinical PAH – A Provocative Debate  /  Debate: Targeting Inflammation is Not a Viable Therapeutic Avenue for PAH
Logo

American Heart Association

  78
  0

Final ID:

Debate: Targeting Inflammation is Not a Viable Therapeutic Avenue for PAH

  • Yu, Paul  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Rhodes, Christopher  ( Imperial College London , London , United Kingdom )
  • Wilkins, M  ( Imperial College , London , United Kingdom )
    • Author Disclosures:
    Paul Yu: DO have relevant financial relationships ; Ownership Interest:Keros Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Gossamer Bio:Active (exists now) ; Consultant:OrphAi:Active (exists now) ; Research Funding (PI or named investigator):AllRock:Active (exists now) ; Research Funding (PI or named investigator):Ingenia Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) | Christopher Rhodes: No Answer | M Wilkins: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Inflammation in Preclinical vs. Clinical PAH – A Provocative Debate

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Inflammation and Right Ventricular Failure : Is This the Missing Link?

Pullamsetti Soni Savai, Prisco Sasha, Bogaard Harm

Inflammation and Pulmonary Vascular Remodeling: Cause or Consequence?

Kuebler Wolfgang, Yu Yen-rei, Prins Kurt

More abstracts from these authors:
Mentor

Yu Paul

Epigenetic Age in Pulmonary Hypertension: Is it Relevant?

Potus Francois, Rhodes Christopher

You have to be authorized to contact abstract author. Please, Login
Not Available